HER2/ERBB2 and Genomic Alterations in Patients with Gallbladder Cancer from Argentina
4 affiliations
- 1ILOGI (Latin American Intergroup of Gatrointestinal Oncology), San Salvador de Jujuy 4600, Jujuy, Argentina
- 2San Isidro Patología, San Isidro 1642, Provincia de Buenos Aires, Argentina
- 3Centro de Investigación del Cáncer Rosario y Cox Analíticas, Rosario 2000, Santa Fe, Argentina
- 4Department of Hematology-Oncology, Mayo Clinic Cancer Center, Phoenix, AZ 85054, USA
Abstract
Background/Objectives: Gallbladder cancer (GBC) is highly prevalent in Western Argentina, where the frequency and clinical significance of HER2/ERBB2 abnormalities remain unknown. We investigated the prevalence, prognostic impact, and genomic co-occurrence of HER2/ERBB2 alterations in Argentine patients with GBC. Methods: We retrospectively analyzed patients with GBC from the Latin American Intergroup of Gastrointestinal Oncology (ILOGI) database. HER2 protein expression was assessed by immunohistochemistry, and sequence variants in ERBB2 and 213 other cancer-related genes by next-generation sequencing. Overall survival (OS) was analyzed using Kaplan–Meier curves, the log-rank test, and univariate Cox proportional hazards regression. Genomic co-occurrences were evaluated using Fisher’s exact test. Results: Thirty patients were included in the study. Most were women with gallstones and advanced-stage disease. HER2 overexpression was detected in five patients (17%), with ERBB2 variants in three other tumors, yielding an overall HER2/ERBB2 alteration rate of 27% (8/30). Among patients with stage III–IV disease, HER2/ERBB2 abnormalities were not associated with a statistically significant difference in OS (HR, 0.40; 95% CI, 0.11–1.45; p = 0.162). Similarly, HER2 overexpression alone had no significant prognostic impact. Exploratory analysis identified potential co-occurrence of HER2/ERBB2 abnormalities with sequence variants in 16 genes involved in chemotherapy sensitivity and the PI3K/AKT/mTOR and VEGF signaling pathways, although these associations were not statistically significant after correction for multiple comparisons. Conclusions: HER2/ERBB2 abnormalities are frequent among Argentine patients with GBC and do not appear to be associated with poorer OS. Our findings provide a biologic rationale for further investigation of the potential synergistic effects of combining anti-HER2 therapies with PI3K/AKT/mTOR or VEGF pathway inhibitors.
Related
- Tumor genomic alterations and their exploratory association with treatment response in recurrent head and neck cancer patients
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer
- Clinically actionable genomic alterations in breast cancer brain metastases
- Integrated Genomic and Immune Profiling Reveals PIK3CA-Mutant HPV16-Positive Cervical Cancer as a Clinically Aggressive and Immunologically Distinct Subtype in Patients from Eastern India
- Gene Expression Alterations of TIMP3, ELASTIN, K-RAS, and BRAF in Colorectal Cancer Patients with H. pylori Infection
BibTeX
@article{arroyo2026her2erbb2,
title = {{HER2/ERBB2 and Genomic Alterations in Patients with Gallbladder Cancer from Argentina}},
author = {Gerardo F. Arroyo and Gabriela I. Acosta Haab and Aylén Avila and Oluseyi B. Abidoye and Elizabeth A. Raupach and Esteban Braggio and Mitesh J. Borad},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18213461},
url = {https://www.mdpi.com/2072-6694/18/21/3461},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - HER2/ERBB2 and Genomic Alterations in Patients with Gallbladder Cancer from Argentina
AU - Gerardo F. Arroyo
AU - Gabriela I. Acosta Haab
AU - Aylén Avila
AU - Oluseyi B. Abidoye
AU - Elizabeth A. Raupach
AU - Esteban Braggio
AU - Mitesh J. Borad
PY - 2026
DA - 2026/10/27
JO - Cancers
DO - 10.3390/cancers18213461
UR - https://www.mdpi.com/2072-6694/18/21/3461
AB - Background/Objectives: Gallbladder cancer (GBC) is highly prevalent in Western Argentina, where the frequency and clinical significance of HER2/ERBB2 abnormalities remain unknown. We investigated the prevalence, prognostic impact, and genomic co-occurrence of HER2/ERBB2 alterations in Argentine patients with GBC. Methods: We retrospectively analyzed patients with GBC from the Latin American Intergroup of Gastrointestinal Oncology (ILOGI) database. HER2 protein expression was assessed by immunohistochemistry, and sequence variants in ERBB2 and 213 other cancer-related genes by next-generation sequencing. Overall survival (OS) was analyzed using Kaplan–Meier curves, the log-rank test, and univariate Cox proportional hazards regression. Genomic co-occurrences were evaluated using Fisher’s exact test. Results: Thirty patients were included in the study. Most were women with gallstones and advanced-stage disease. HER2 overexpression was detected in five patients (17%), with ERBB2 variants in three other tumors, yielding an overall HER2/ERBB2 alteration rate of 27% (8/30). Among patients with stage III–IV disease, HER2/ERBB2 abnormalities were not associated with a statistically significant difference in OS (HR, 0.40; 95% CI, 0.11–1.45; p = 0.162). Similarly, HER2 overexpression alone had no significant prognostic impact. Exploratory analysis identified potential co-occurrence of HER2/ERBB2 abnormalities with sequence variants in 16 genes involved in chemotherapy sensitivity and the PI3K/AKT/mTOR and VEGF signaling pathways, although these associations were not statistically significant after correction for multiple comparisons. Conclusions: HER2/ERBB2 abnormalities are frequent among Argentine patients with GBC and do not appear to be associated with poorer OS. Our findings provide a biologic rationale for further investigation of the potential synergistic effects of combining anti-HER2 therapies with PI3K/AKT/mTOR or VEGF pathway inhibitors.
SN - 2072-6694
ER -